专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20100256379A1 ANTI-VIRAL AGENT CONTAINING HETEROCYCLIC AROMATIC COMPOUND AS ACTIVE INGREDIENT 审中-公开
标题翻译：含有作为活性成分的杂环芳族化合物的抗病毒剂
公开(公告)号：US20100256379A1
公开(公告)日：2010-10-07
申请号：US12739795
申请日：2008-10-22
申请人： Masanori Baba , Yuichi Hashimoto , Hiroshi Aoyama , Kumiko Sako , Shinichi Sato , Katsuyuki Nagai
发明人： Masanori Baba , Yuichi Hashimoto , Hiroshi Aoyama , Kumiko Sako , Shinichi Sato , Katsuyuki Nagai
IPC分类号： C07D471/04
CPC分类号： C07D209/86 , C07D307/91 , C07D471/04
摘要： The present invention relates to an anti-viral agent comprising a compound represented by the following formula (I): (wherein X represents CH, a nitrogen atom, an oxygen atom, or a sulfur atom; Y and Z are the same or different and each represents a nitrogen atom or C—R8, and at least one of them represents a nitrogen atom; R1 to R8 are the same or different and each represents a hydrogen atom, a linear C1-10-hydrocarbon group, a hydroxy group, or a substituted or unsubstituted benzyl group; and, when X represents an oxygen atom or a sulfur atom, R5 is absent), or the following formula (II): (wherein X′ represents CH or a nitrogen atom; Y′ and Z′ are the same or different and each represents a nitrogen atom or N—R9, or C—R8 and at least one of them represents a nitrogen atom or N—R9; R1 to R4 and R6 to R8 are as defined above; R9 represents a hydrogen atom, a linear C1-10-hydrocarbon group, a hydroxy group, or a substituted or unsubstituted benzyl group; and, the C ring has the maximum number of double bonds at the dotted line portion) or a pharmaceutically acceptable salt thereof.
摘要翻译：本发明涉及包含由下式（I）表示的化合物的抗病毒剂：（其中X表示CH，氮原子，氧原子或硫原子; Y和Z相同或不同，各自表示氮原子或C-R8，并且其中至少一个表示氮原子; R 1〜R 8相同或不同，表示氢原子，直链C 1-10烃基，羟基或取代或未取代的苄基;当X表示氧原子或硫原子时，R 5不存在）或下式（II）表示：（其中X'表示CH或氮原子，Y'和Z'为相同或不同，各自表示氮原子或N-R9或C-R8，并且其中至少一个表示氮原子或N-R 9; R 1至R 4和R 6至R 8如上所定义; R 9表示氢原子，直链C 1-10烃基，羟基或取代或未取代的苄基;和C环h 作为虚线部分的双键的最大数目）或其药学上可接受的盐。

2. 发明申请

US20120316342A1 THERAPEUTIC AGENT FOR HEPATITIS C 审中-公开
标题翻译：乙型肝炎治疗药物C
公开(公告)号：US20120316342A1
公开(公告)日：2012-12-13
申请号：US13576269
申请日：2011-01-31
申请人： Masanori Baba , Yuichi Hashimoto , Hiroshi Aoyama , Kazuyuki Sugita , Masahiko Nakamura , Atsushi Aoyama , Yasuo Urata
发明人： Masanori Baba , Yuichi Hashimoto , Hiroshi Aoyama , Kazuyuki Sugita , Masahiko Nakamura , Atsushi Aoyama , Yasuo Urata
IPC分类号： C07D221/12 , C07D491/056 , C07D221/18
CPC分类号： C07D221/12 , A61K31/473
摘要： This invention provides a therapeutic agent for hepatitis C comprising, as an active ingredient, a compound having anti-HCV activity useful in treatment of hepatitis C. The therapeutic agent for hepatitis C comprises, as an active ingredient, a compound represented by formula (I) or a pharmaceutically acceptable salt thereof.
摘要翻译：本发明提供一种丙型肝炎治疗剂，其包含作为活性成分的具有抗HCV活性的化合物，其用于治疗丙型肝炎。丙型肝炎治疗剂包含作为活性成分的式（I ）或其药学上可接受的盐。

3. 发明授权

US08765719B2 Therapeutic drug for adult T-cell leukemia 有权
标题翻译：成人T细胞白血病治疗药物
公开(公告)号：US08765719B2
公开(公告)日：2014-07-01
申请号：US13120114
申请日：2009-08-20
申请人： Masanori Baba , Yuichi Hashimoto
发明人： Masanori Baba , Yuichi Hashimoto
IPC分类号： A61K31/12 , A61K31/166 , A61K31/11 , A61K31/695 , A61K31/352 , A61K31/095 , A61K31/135 , C07C49/83 , C07C325/02 , C07C233/65 , C07C47/546 , C07F7/08 , C07C225/18
CPC分类号： C07C49/83 , A61K31/10 , A61K31/11 , A61K31/12 , A61K31/166 , A61K31/352 , A61K31/695
摘要： An object is to provide a novel therapeutic drug for adult T-cell leukemia having an ATL cell specific antitumor effect. The therapeutic drug for adult T-cell leukemia according to the invention is characterized by containing a compound represented by the formula I or a prodrug thereof, wherein R1 is H, OH, an alkoxy group, an acyl group, or a thioacyl group, R2 is an acyl group, a thioacyl group, CONR7R8, or CSNR7R8 (R7 and R8 being each independently H, an alkyl group containing 1 to 3 carbon atoms, or a phenyl group), or R1 and R2 together may form a ring, X1 and X2 may be the same or different and are each —CR3R4—, —SiR3R4— or oxygen, and R3 and R4 may be the same or different and are each an alkyl group containing 1 to 6 carbon atoms.
摘要翻译：目的是提供一种具有ATL细胞特异性抗肿瘤作用的成人T细胞白血病的新型治疗药物。根据本发明的成人T细胞白血病的治疗药物的特征在于含有式I化合物或其前体药物，其中R1是H，OH，烷氧基，酰基或硫代酰基，R2 是酰基，硫代酰基，CONR7R8或CSNR7R8（R7和R8各自独立地为H，含有1至3个碳原子的烷基或苯基），或者R1和R2一起可以形成环，X1和 X2可以相同或不同，各自为-CR 3 R 4 - ， - SiR 3 R 4 - 或氧，R 3和R 4可以相同或不同，并且各自为含有1至6个碳原子的烷基。

4. 发明申请

US20110172185A1 THERAPEUTIC DRUG FOR ADULT T-CELL LEUKEMIA 有权
标题翻译：用于成人T细胞淋巴瘤的治疗药物
公开(公告)号：US20110172185A1
公开(公告)日：2011-07-14
申请号：US13120114
申请日：2009-08-22
申请人： Masanori Baba , Yuichi Hashimoto
发明人： Masanori Baba , Yuichi Hashimoto
IPC分类号： A61K31/12 , A61K31/166 , A61K31/11 , A61K31/695 , A61K31/352 , A61K31/095 , A61K31/135 , C07C49/83 , C07C325/02 , C07C233/65 , C07C47/546 , C07F7/08 , C07C225/18 , C07D311/92 , A61P35/02
CPC分类号： C07C49/83 , A61K31/10 , A61K31/11 , A61K31/12 , A61K31/166 , A61K31/352 , A61K31/695
摘要： An object is to provide a novel therapeutic drug for adult T-cell leukemia having an ATL cell specific antitumor effect. The therapeutic drug for adult T-cell leukemia according to the invention is characterized by containing a compound represented by the formula I or a prodrug thereof, wherein R1 is H, OH, an alkoxy group, an acyl group, or a thioacyl group, R2 is an acyl group, a thioacyl group, CONR7R8, or CSNR7R8 (R7 and R8 being each independently H, an alkyl group containing 1 to 3 carbon atoms, or a phenyl group), or R1 and R2 together may form a ring, X1 and X2 may be the same or different and are each —CR3R4—, —SiR3R4— or oxygen, and R3 and R4 may be the same or different and are each an alkyl group containing 1 to 6 carbon atoms.
摘要翻译：目的是提供一种具有ATL细胞特异性抗肿瘤作用的成人T细胞白血病的新型治疗药物。根据本发明的成人T细胞白血病的治疗药物的特征在于含有式I化合物或其前体药物，其中R1是H，OH，烷氧基，酰基或硫代酰基，R2 是酰基，硫代酰基，CONR7R8或CSNR7R8（R7和R8各自独立地为H，含有1至3个碳原子的烷基或苯基），或者R1和R2一起可以形成环，X1和 X2可以相同或不同，各自为-CR 3 R 4 - ， - SiR 3 R 4 - 或氧，R 3和R 4可以相同或不同，并且各自为含有1至6个碳原子的烷基。

5. 发明授权

US08741943B2 Bicyclic compound, production and use thereof 有权
标题翻译：双环化合物，其生产和使用
公开(公告)号：US08741943B2
公开(公告)日：2014-06-03
申请号：US13476454
申请日：2012-05-21
申请人： Mitsuru Shiraishi , Masanori Baba , Katsuji Aikawa , Naoyuki Kanzaki , Masaki Seto , Yuji Iizawa
发明人： Mitsuru Shiraishi , Masanori Baba , Katsuji Aikawa , Naoyuki Kanzaki , Masaki Seto , Yuji Iizawa
IPC分类号： C07D403/02 , A61K31/4178
CPC分类号： A61K31/4196 , A61K31/395 , A61K31/4178 , C07D225/06 , C07D313/20 , C07D403/12 , C07D405/12 , C07D407/12
摘要： The present invention provides a new cyclic compound having a CCR antagonist activity, especially a CCR5 antagonist activity, and the use thereof. The compound of the present invention is represented by the formula: wherein, R1 is a 5- to 6-membered ring group which may be substituted; X1 is a bond or the like; ring A is a 5- to 6-membered ring group which may be substituted; ring B is a 8- to 10-membered ring group which may be substituted; X2 is a bivalent group of 1 to 4 atoms; Z1 is a bivalent cyclic ring group or the like; Z2 is a bond or the like; and R2 is an amino group, a nitrogen-containing heterocyclic group which may be substituted or the like, or a salt thereof.
摘要翻译：本发明提供具有CCR拮抗剂活性，特别是CCR5拮抗剂活性的新的环状化合物及其用途。本发明化合物由下式表示：其中，R 1为可被取代的5-至6-元环基; X1是债券等; 环A是可以被取代的5至6元环基团; 环B是可以被取代的8至10元环基团; X 2是1至4个原子的二价基团; Z1是二价环状环基等; Z2是键或类似物; R 2为氨基，可以被取代的含氮杂环基等，或其盐。

6. 发明申请

US20110117602A1 HUMAN ANTIBODY CAPABLE OF INDUCING APOPTOSIS 审中-公开
标题翻译：人类抗体可诱导疫苗
公开(公告)号：US20110117602A1
公开(公告)日：2011-05-19
申请号：US12743739
申请日：2008-11-18
申请人： Yuji Ito , Masanori Baba , Naomichi Arima , Yasuo Suda , Toshihiro Nakashima , Masaharu Torikai
发明人： Yuji Ito , Masanori Baba , Naomichi Arima , Yasuo Suda , Toshihiro Nakashima , Masaharu Torikai
IPC分类号： C07K16/30 , C07H21/04 , C12N15/63 , C12P21/00
CPC分类号： C07K16/005 , C07K16/2833 , C07K2317/56 , C07K2317/565 , C07K2317/622 , C07K2317/73 , G01N33/57484
摘要： A human antibody that has a specific reactivity with multiple tumor cell lines including ATL cells and possesses both safety and therapeutic efficacy and a fragment of said antibody are provided. A human antibody and a fragment of said antibody that may recognize HLA-DR β chain expressed on the surface of tumor cells were obtained. In particular, it was found that a dimer of scFv (diabody) of said antibody may induce potent apoptosis in cells expressing the HLA-DR β chain. The antibody and a fragment of said antibody obtained in accordance with the present invention are useful for a detection reagent, a diagnostic and a medicament for protection or treatment of cancers including ATL and/or viral infectious diseases.
摘要翻译：提供了与多种肿瘤细胞系（包括ATL细胞）具有特异性反应性并具有安全性和治疗功效以及所述抗体片段的人类抗体。可以识别HLA-DR和bgr的人抗体和所述抗体的片段; 获得在肿瘤细胞表面表达的链。特别地，发现所述抗体的scFv（双抗体）的二聚体可能在表达HLA-DR和bgr的细胞中诱导有效的凋亡; 链。根据本发明获得的抗体和所述抗体的片段可用于检测试剂，诊断剂和用于保护或治疗包括ATL和/或病毒感染性疾病的癌症的药物。

7. 发明申请

US20060178359A1 Tricyclic compound, process for producing the same, and use 审中-公开
标题翻译：三环化合物，其制备方法和用途
公开(公告)号：US20060178359A1
公开(公告)日：2006-08-10
申请号：US10544470
申请日：2004-02-05
申请人： Mitsuru Shiraishi , Masaki Seto , Katsuji Aikawa , Naoyuki Kanzaki , Masanori Baba
发明人： Mitsuru Shiraishi , Masaki Seto , Katsuji Aikawa , Naoyuki Kanzaki , Masanori Baba
IPC分类号： A61K31/55 , A61K31/4745 , C07D487/14
CPC分类号： C07D471/04 , A61K31/4353 , A61K31/55
摘要： A compound of the formula: wherein R1 is a 5- or 6-membered ring; Z1 is a 5- or 6-membered aromatic ring; Z2 is a group -Z2a-W2-Z2b-, wherein Z2a and Z2b are each O, S(O)q (wherein q is 0, 1 or 2), an imino group, or a bond; and W2 is an alkylene chain; W is a group represented by wherein R3 and R3′ are each a hydrogen atom, a lower alkyl group, or a lower alkoxy group; X is CH or N; n and n′ are each an integer of 0 or 1 to 4; m and m′ are each 1 or 2; Y is O, S(O)p (wherein p is 0, 1 or 2), CH2 or NR4 (wherein R4 is a hydrogen atom, a lower alkyl group, or a lower acyl group); and R2 is (1) an amino group, in which the nitrogen atom may be converted to a quaternary ammonium or an oxide, or (2) a nitrogen-containing heterocyclic group which may contain a sulfur atom or an oxygen atom as the ring-constituting atom, in which the nitrogen atom may be converted to a quaternary ammonium or an oxide; or a salt thereof. The compound exhibits excellent CCR antagonist activity against CCR5, and is useful as a prophylactic and/or therapeutic agent for HIV infection in human peripheral blood mononuclear cells, especially for AIDS.
摘要翻译：下式的化合物：其中R 1是5或6元环; Z 1是5或6元芳环; Z 2是基团-Z 2 O 2 -W 2 -Z 2b 2，其中Z 2a 和/或O 2各自为O，S（O）q q（其中q为0,1或2），亚氨基或键; 和W 2是亚烷基链; W是由R 3和R 3'表示的基团各自为氢原子，低级烷基或低级烷氧基; X是CH或N; n和n'各自为0或1〜4的整数; m和m'分别为1或2; Y是O，S（O）p（其中p是0,1或2），CH 2或NR 4（其中R' SUP> 4 是氢原子，低级烷基或低级酰基）; R 2是（1）可以将氮原子转化为季铵或氧化物的氨基，或者（2）可含有硫原子的含氮杂环基或氧原子作为构成环的原子，其中氮原子可以转化为季铵或氧化物; 或其盐。该化合物对CCR5表现出优异的CCR拮抗剂活性，并且可用作人外周血单核细胞（特别是AIDS）中HIV感染的预防和/或治疗剂。

8. 发明申请

US20050154016A1 Preventives for hiv infection 审中-公开
标题翻译：预防HIV感染
公开(公告)号：US20050154016A1
公开(公告)日：2005-07-14
申请号：US10511531
申请日：2003-04-17
申请人： Katsunori Takashima , Yuji Iizawa , Mitsuru Shiraishi , Yoshihiro Sugihara , Masanori Baba
发明人： Katsunori Takashima , Yuji Iizawa , Mitsuru Shiraishi , Yoshihiro Sugihara , Masanori Baba
IPC分类号： A61K31/445 , A61K31/452 , A61K31/454 , A61K31/4545 , A61K31/55 , A61P31/18 , A61P37/04
CPC分类号： A61K31/445 , A61K31/452 , A61K31/454 , A61K31/4545 , A61K31/55
摘要： It is intended to provide a novel drug which exhibits an excellent effect of preventing HIV infection in transfusing blood and using a blood preparation. This object can be achieved by a preventive for HIV infection in transfusing blood and using a blood prepartion characterized by containing a compound having an antagonism to a CC chemokine receptor (preferably antagonism to CCR5 and/or CCR2).
摘要翻译：旨在提供一种在输血和使用血液制剂中具有优异的预防HIV感染效果的新型药物。该目的可以通过预防HIV感染来预防输血，并使用血液制剂，其特征在于含有对CC趋化因子受体具有拮抗作用的化合物（优选对CCR5和/或CCR2的拮抗作用）。

9. 发明授权

US06627651B1 Cyclic compounds and uses thereof 失效
标题翻译：环状化合物及其用途
公开(公告)号：US06627651B1
公开(公告)日：2003-09-30
申请号：US09980773
申请日：2001-11-02
申请人： Mitsuru Shiraishi , Masanori Baba , Masaki Seto , Naoyuki Kanzaki , Osamu Nishimura
发明人： Mitsuru Shiraishi , Masanori Baba , Masaki Seto , Naoyuki Kanzaki , Osamu Nishimura
IPC分类号： A61K3138
CPC分类号： C07D405/12 , A61K31/351 , A61K31/352 , A61K31/381 , A61K31/4025 , A61K31/44 , A61K31/4709 , A61K31/4725 , A61K31/661 , C07D217/06 , C07D309/08 , C07D313/08 , C07D405/14 , C07D407/12 , C07D409/12 , C07D409/14 , C07F9/65517
摘要： Compounds of general formula (1) R1—X1—W—X2—Z1—Z2—R2 or salts thereof, exhibiting preventive and therapeutic effects against HIV infectious diseases wherein R1 is an optionally substituted five- or six-membered ring group; X1 is a free valency or the like; W is a divalent group represented by, e. g., general formula (2) (wherein A and B are each an optionally substituted five- to seven-membered ring; E1 and E4 are each optionally substituted carbon or the like; E2 and E3 are each oxygen or the like; and a and b are each a single bond or a double bond); X2 is a divalent group constituting a straight chain moiety; Z1 is a divalent cyclic group or the like; Z2 is a free valency or the like; and R2 is optionally substituted amino or the like.
摘要翻译：通式（1）的化合物或其盐，表现出对HIV感染性疾病的预防和治疗作用，其中R 1为任选取代的五元或六元环基团; X 1是自由价或类似物; W是由e表示的二价基团。例如通式（2）（其中A和B各自为任选取代的五至七元环; E1和E4各自为任选取代的碳等; E2和E3各自为氧等; 和b各自为单键或双键）; X 2是构成直链部分的二价基团; Z 1是二价的环状基团等; Z 2是自由价或类似物; 和R 2是任选取代的氨基等。

10. 发明授权

US06172061B2 Pharmaceutical composition for antagonizing CCR5 comprising anilide derivative 失效
公开(公告)号：US06172061B2
公开(公告)日：2001-01-09
申请号：US09213377
申请日：1998-12-17
申请人： Osamu Nishimura , Masanori Baba , Hidekazu Sawada , Naoyuki Kanzaki , Ken-ichi Kuroshima , Mitsuru Shiraishi , Yoshio Aramaki
发明人： Osamu Nishimura , Masanori Baba , Hidekazu Sawada , Naoyuki Kanzaki , Ken-ichi Kuroshima , Mitsuru Shiraishi , Yoshio Aramaki
IPC分类号： A62K31351
CPC分类号： C07D407/12 , A61K31/335 , A61K31/351 , A61K31/452 , A61K31/4523 , A61K31/5377 , A61K31/665 , A61K31/67 , A61K45/06 , C07C233/62 , C07C2602/12 , C07D309/14 , C07D313/08 , C07D337/08
摘要： This invention is to provide a pharmaceutical composition for antagonizing CCR5 which comprises a compound of the formula: wherein R1 is an optionally substituted 5- to 6-membered ring; W is a divalent group of the formula: wherein the ring A is an optionally substituted 5- to 6-membered aromatic ring, X is an optionally substituted C, N or O atom, and the ring B is an optionally substituted 5- to 7-membered ring; Z is a chemical bond or a divalent group; R2 is (1) an optionally substituted amino group in which a nitrogen atom may form a quaternary ammonium, etc., or a salt thereof.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式